



Interactive Table Discussion Questions

The following questions have been developed to guide the interactive discussion at the individual tables. Each session will begin with brief introductory presentations followed by a 60-minute discussion using the questions below. Individual tables will then report back to the full group with a topline summary of the key issues discussed.

Please select a representative from your table for each session to take notes and report back to the full group at the end of discussion.

SESSION 1: DEFINING THE LANDSCAPE FOR TROPONIN TESTING

Presentations:

- Who Should Have a Troponin Measured?
- Should All Hospitals Transition to hs-cTn testing?
- Does the 99th Percentile cTn Value Mean Anything to The Clinician?

Discussion Questions:

1. Are we overutilizing troponin testing? And if so, what factors are driving this? Who should have a high-sensitivity troponin drawn?
 2. Should all hospitals transition to high-sensitivity troponin assays? If not, what additional data is needed to do so?
 3. What are the implications of using or not using 99th percentile cut points? How does the FDA choice of diagnostic values affect ADP protocols? How should sex and age influence threshold values?
-

SESSION 2: BIOMARKER BASED STRATEGIES FOR EXCLUSION OF ACUTE MI

Presentations:

- An International Perspective
- A U.S. Perspective
- Role of Clinical Factors and EKG

Discussion Questions:

1. What are the differences in the non-U.S. data that could affect application in the U.S.?



2. Are the US data sufficiently compelling to make recommendations at this point? If not, what else is needed?
 3. How should EKG and clinical factors be considered? Should a risk score be used? If so, is there a preference for which one? How should the risk score be integrated with the troponin values?
 4. How should we triage patients with baseline troponin elevations e.g. myocardial injury from CKD, chronic HF, etc? Should ACC include this in policy document development?
 5. What education is needed before implementing a hs-cTn ADP?
-

SESSION 3: ROLE OF NONINVASIVE TESTING

Presentations:

- Who Should Receive Noninvasive Testing Beyond cTn?
- Which Test for Which Patient?
- What Should Be Done with the Test Results?
- Shared Decision-Making: The Patient Perspective

Discussion Questions:

1. For patients who rule out, should further evaluation be performed? If so, in whom? Is there a preferred imaging test?
2. For patients who neither rule in or rule out with indeterminate troponin results, what type of evaluation should be performed?
3. How should diagnostic strategies differ for patients with and without known CAD?
4. What to do overnight and on the weekend?
5. How can we effectively engage patients in shared decision-making? Is there a role for an app or visual tool to help systematize patient engagement?